PYXS to host webcast with updated Phase 1 MICVO data
Pyxis Oncology will host a webcast to present updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in 2L+ recurrent/metastatic head and neck squamous cell carcinoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.